{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:08:49Z","timestamp":1790100529074,"version":"4.0.1"},"reference-count":60,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-medical androgen use, commonly involving anabolic\u2013androgenic steroids, represents an increasing public health concern. Non-medical androgen use is associated with significant morbidity and mortality, including cardiovascular disease, erythrocytosis, dyslipidaemia, infertility, sexual dysfunction, psychiatric manifestations and suppression of the hypothalamic\u2013pituitary\u2013gonadal axis. Men with current or previous non-medical androgen use are increasingly presenting to endocrine and reproductive medicine services, often with hypogonadal symptoms, infertility or concerns regarding recovery following cessation. However, both patients and clinicians frequently report mistrust, uncertainty and limited confidence in management approaches. This Society for Endocrinology position statement summarises the currently available evidence relating to non-medical androgen use, associated health consequences, biochemical recovery following cessation and potential management strategies. Current evidence suggests that most men will experience biochemical recovery of the HPG axis within approximately 12 months of androgen cessation, although recovery timelines vary substantially and some individuals may develop persistent hypogonadism. Symptoms such as low mood, fatigue, anxiety and sexual dysfunction may persist despite biochemical recovery and are likely influenced by psychological factors in addition to serum testosterone concentrations. Existing evidence supporting pharmacological interventions, including human chorionic gonadotrophin, selective oestrogen receptor modulators, aromatase inhibitors or testosterone therapy, remains limited and of low quality, with no robust evidence demonstrating improved long-term recovery or symptom outcomes. Clinicians should approach individuals who misuse androgens with compassion, professionalism and a non-judgemental attitude while remaining alert to undisclosed androgen use. Further longitudinal and interventional studies are required to better characterise recovery trajectories, identify predictors of persistent morbidity and inform evidence-based management strategies.<\/jats:p>","DOI":"10.1530\/ec-26-0361","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:30:01Z","timestamp":1788535801000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Management of non-medical androgen use: a position statement by the Society for Endocrinology"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1121-9211","authenticated-orcid":true,"given":"Bonnie","family":"Grant","sequence":"first","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London 1 , ,","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-8223","authenticated-orcid":true,"given":"Channa N","family":"Jayasena","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London 1 , ,","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Nag","sequence":"additional","affiliation":[{"name":"James Cook University Hospital, South Tees Hospitals NHS Foundation Trust 2 , ,","place":["Middlesbrough, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-8095","authenticated-orcid":true,"given":"Richard","family":"Quinton","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London 1 , ,","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026092213512417500_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","article-title":"The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis","volume":"24","author":"Sagoe","year":"2014","journal-title":"Ann Epidemiol"},{"key":"2026092213512417500_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09687637.2022.2070058","article-title":"Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise","volume":"30","author":"Hope","year":"2022","journal-title":"Drugs Educ Prev Pol"},{"key":"2026092213512417500_bib3","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/bph.14995","article-title":"Anabolic androgenic steroid abuse in the United Kingdom: an update","volume":"177","author":"Mullen","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2026092213512417500_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026092213512417500_bib5","article-title":"Nandrolone decanoate for postmenopausal osteoporosis: a systematic review and meta-analysis of randomized trials","volume":"17","author":"Camara","year":"2025","journal-title":"Cureus"},{"key":"2026092213512417500_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320966536","article-title":"Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men","volume":"14","author":"Bonnecaze","year":"2020","journal-title":"Am J Mens Health"},{"key":"2026092213512417500_bib7","author":"Begley","year":"2017"},{"key":"2026092213512417500_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1550-2783-4-12","article-title":"A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States","volume":"4","author":"Cohen","year":"2007","journal-title":"J Int Soc Sports Nutr"},{"key":"2026092213512417500_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1177\/1557988316648704","article-title":"The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the internet","volume":"12","author":"McBride","year":"2018","journal-title":"Am J Mens Health"},{"key":"2026092213512417500_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.biopsych.2011.06.024","article-title":"Risk factors for illicit anabolic-androgenic steroid use in male weightlifters: a cross-sectional cohort study","volume":"71","author":"Pope","year":"2012","journal-title":"Biol Psychiatry"},{"key":"2026092213512417500_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0376-8716(03)00069-3","article-title":"Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study","volume":"71","author":"Kanayama","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"2026092213512417500_bib12","article-title":"Causal factors in childhood and adolescence leading to anabolic-androgenic steroid use: a machine learning approach","volume":"10","author":"Hudson","year":"2024","journal-title":"Drug Alcohol Dependence Rep"},{"key":"2026092213512417500_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11088","article-title":"Exploring anabolic androgenic steroid use among cisgender gay, bisexual, and queer men","volume":"7","author":"Kutscher","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026092213512417500_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/joim.12850","article-title":"Health consequences of androgenic anabolic steroid use","volume":"285","author":"Horwitz","year":"2019","journal-title":"J Intern Med"},{"key":"2026092213512417500_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.15187","article-title":"Androgen abuse: risks and adverse effects in men","volume":"1538","author":"Grant","year":"2024","journal-title":"Ann N Y Acad Sci"},{"key":"2026092213512417500_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/and.14372","article-title":"Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse","volume":"54","author":"Smit","year":"2022","journal-title":"Andrologia"},{"key":"2026092213512417500_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.124.071117","article-title":"Cardiovascular disease in anabolic androgenic steroid users","volume":"151","author":"Windfeld-Mathiasen","year":"2025","journal-title":"Circulation"},{"key":"2026092213512417500_bib18","first-page":"261","article-title":"Spontaneous haemorrhage of hepatic adenoma in a patient addicted to anabolic steroids","volume":"77","author":"Smit","year":"2019","journal-title":"Neth J Med"},{"key":"2026092213512417500_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.mehy.2016.06.004","article-title":"Anabolic androgenic steroid-induced hepatotoxicity","volume":"93","author":"Bond","year":"2016","journal-title":"Med Hypotheses"},{"key":"2026092213512417500_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003207","article-title":"Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study","volume":"3","author":"Hope","year":"2013","journal-title":"BMJ Open"},{"key":"2026092213512417500_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.1994.03950050035004","article-title":"Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes","volume":"51","author":"Pope","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"2026092213512417500_bib22","first-page":"579","article-title":"Long-term anabolic\u2013androgenic steroid use is associated with deviant brain aging","volume":"6","author":"Bj\u00f8rnebekk","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2026092213512417500_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugalcdep.2015.04.023","article-title":"Brain and cognition abnormalities in long-term anabolic-androgenic steroid users","volume":"152","author":"Kaufman","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2026092213512417500_bib24","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.juro.2013.06.010","article-title":"Anabolic steroid induced hypogonadism in young men","volume":"190","author":"Coward","year":"2013","journal-title":"J Urol"},{"key":"2026092213512417500_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1360-0443.2004.00781.x","article-title":"Anabolic steroid users\u2019 attitudes towards physicians","volume":"99","author":"Pope","year":"2004","journal-title":"Addiction"},{"key":"2026092213512417500_bib26","doi-asserted-by":"crossref","DOI":"10.1530\/RAF-22-0097","article-title":"Survey of endocrinologists managing recovery from anabolic androgenic steroid induced hypogonadism","volume":"4","author":"Grant","year":"2023","journal-title":"Reprod Fertil"},{"key":"2026092213512417500_bib27","article-title":"Two sides of the same coin: a qualitative exploration of experiential and perceptual factors which influence the clinical interaction between physicians and Anabolic-Androgenic Steroid using patients in the UK","volume":"2","author":"Ainsworth","year":"2022","journal-title":"Emerg Trends Drugs Addict Health"},{"key":"2026092213512417500_bib28","doi-asserted-by":"crossref","first-page":"e3790","DOI":"10.1210\/clinem\/dgac348","article-title":"Reliability of drug history to verify androgen abuse in men","volume":"107","author":"Shankara-Narayana","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213512417500_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.2007.03001.x","article-title":"Muscular exercise can cause highly pathological liver function tests in healthy men","volume":"65","author":"Pettersson","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2026092213512417500_bib30","volume-title":"WADA Technical Document - TD2021EAAS Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile","author":"World Anti-Doping Agency","year":"2021"},{"key":"2026092213512417500_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2023.109199","article-title":"Androgenic steroids in over-the-counter dietary supplements: analysis for association with adverse health effects","volume":"193","author":"Tran","year":"2023","journal-title":"Steroids"},{"key":"2026092213512417500_bib32","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0283","article-title":"Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?","volume":"13","author":"Bond","year":"2024","journal-title":"Endocr Connect"},{"key":"2026092213512417500_bib33","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1210\/clinem\/dgz324","article-title":"Rate and extent of recovery from reproductive and cardiac dysfunction due to androgen abuse in men","volume":"105","author":"Shankara-Narayana","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213512417500_bib34","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/humrep\/deaa366","article-title":"Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study","volume":"36","author":"Smit","year":"2021","journal-title":"Hum Reprod"},{"key":"2026092213512417500_bib35","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0358","article-title":"Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review","volume":"12","author":"Solanki","year":"2023","journal-title":"Endocr Connect"},{"key":"2026092213512417500_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ejendo\/lvad164","article-title":"Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study","volume":"189","author":"Grant","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026092213512417500_bib37","doi-asserted-by":"crossref","first-page":"e3709","DOI":"10.1210\/clinem\/dgaf157","article-title":"Characterization of leydig cell dysfunction in previous illicit androgen users","volume":"110","author":"Bulut","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213512417500_bib38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1055\/s-0034-1398492","article-title":"The response to gonadotropin-releasing hormone and hCG in men with prior chronic androgen steroid abuse and clinical hypogonadism","volume":"47","author":"Flanagan","year":"2015","journal-title":"Horm Metab Res"},{"key":"2026092213512417500_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13011-023-00573-8","article-title":"The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men","volume":"18","author":"Grant","year":"2023","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"2026092213512417500_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161208","article-title":"Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study","volume":"11","author":"Rasmussen","year":"2016","journal-title":"PLoS One"},{"key":"2026092213512417500_bib41","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1210\/clinem\/dgad551","article-title":"Persistently decreased quality of life and its determinants in previous illicit androgen users","volume":"109","author":"Bulut","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213512417500_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","article-title":"The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates","volume":"23","author":"Pope","year":"2014","journal-title":"Am J Addict"},{"key":"2026092213512417500_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1192\/bjp.2025.73","article-title":"Anabolic-androgenic steroid use disorder: case for recognition as a substance use disorder with specific diagnostic criteria","volume":"228","author":"Scarth","year":"2026","journal-title":"Br J Psychiatr"},{"key":"2026092213512417500_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/17482631.2023.2292826","article-title":"Lived experiences of closeness to a person using Anabolic androgenic steroids a next of kin perspective","volume":"19","author":"B\u00f6rjesson","year":"2024","journal-title":"Int J Qual Stud Health Well-Being"},{"key":"2026092213512417500_bib45","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1210\/clinem\/dgag110","article-title":"Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study","volume":"111","author":"Grant","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213512417500_bib46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/add.12850","article-title":"Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem","volume":"110","author":"Kanayama","year":"2015","journal-title":"Addiction"},{"key":"2026092213512417500_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2023.04.026","article-title":"Long-term risks of depression and suicide among men with prostate cancer: a national cohort study","volume":"84","author":"Crump","year":"2023","journal-title":"Eur Urol"},{"key":"2026092213512417500_bib48","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/jcm10122622","article-title":"Reduced quality of life and sexual satisfaction in isolated hypogonadotropic hypogonadism","volume":"10","author":"Ka\u0142u\u017cna","year":"2021","journal-title":"J Clin Med"},{"key":"2026092213512417500_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/joim.20040","article-title":"Effects of letrozole therapy in former users of anabolic steroids: a randomized clinical trial","volume":"297","author":"Rasmussen","year":"2025","journal-title":"J Intern Med"},{"key":"2026092213512417500_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/and.14576","article-title":"The deleterious effects of anabolic androgenic steroid abuse on sexual and reproductive health and comparison of recovery between treated and untreated patients: single-center prospective randomized study","volume":"54","author":"Al Hashimi","year":"2022","journal-title":"Andrologia"},{"key":"2026092213512417500_bib51","first-page":"120","article-title":"Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data","volume":"6","author":"Smit","year":"2025","journal-title":"F S Rep"},{"key":"2026092213512417500_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.peh.2024.100283","article-title":"Clomiphene citrate and optional human chorionic gonadotropin for treating male hypogonadism arising from long-term anabolic-androgenic steroid use-A pilot study","volume":"12","author":"Henriksen","year":"2024","journal-title":"Perform Enhancement Health"},{"key":"2026092213512417500_bib53","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1345\/aph.1E487","article-title":"Phosphodiesterase 5 inhibitors for erectile dysfunction","volume":"39","author":"Setter","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2026092213512417500_bib54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpedi.1996.02170320059010","article-title":"The adolescents training and learning to avoid steroids (ATLAS) prevention program. Background and results of a model intervention","volume":"150","author":"Goldberg","year":"1996","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2026092213512417500_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bodyim.2022.11.003","article-title":"Goodform: a cluster randomised controlled trial of a school-based program to prevent body dissatisfaction and muscle building supplement use among adolescent boys","volume":"44","author":"Yager","year":"2023","journal-title":"Body Image"},{"key":"2026092213512417500_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.actpsy.2024.104542","article-title":"Efficacy of cognitive-behavioral therapy in reducing muscle dysmorphia symptoms among Turkish gym goers: a pilot study","volume":"250","author":"Cinaroglu","year":"2024","journal-title":"Acta Psychol"},{"key":"2026092213512417500_bib57","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/ph18081081","article-title":"Cognitive behavioral therapy for muscle dysmorphia and anabolic steroid-related psychopathology: a randomized controlled trial","volume":"18","author":"Cinaroglu","year":"2025","journal-title":"Pharmaceuticals"},{"key":"2026092213512417500_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1477-7517-11-19","article-title":"Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study","volume":"11","author":"Kimergard","year":"2014","journal-title":"Harm Reduct J"},{"key":"2026092213512417500_bib59","volume-title":"Services for Image and Performance Enhancing Drug (IPED) Users: Turning Evidence into Practice","author":"Public Health England","year":"2014"},{"key":"2026092213512417500_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ejendo\/lvag002","article-title":"The efficacy of a harm reduction intervention for androgen abuse: a historically controlled trial","volume":"194","author":"Verdegaal","year":"2026","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0361\/524923\/ec-26-0361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0361\/524923\/ec-26-0361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:51:37Z","timestamp":1790099497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/9\/e260361\/78155\/Management-of-non-medical-androgen-use-a-position"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-26-0361","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"e260361"}}